USANA Health Sciences, Inc. — Form 10-Q Summary
Reporting period: Three months ended April 3, 2021, compared with the three months ended March 28, 2020. The request metadata says “2020 Q1,” but the filing is for 2021 Q1; the filing’s comparison period is 2020 Q1. Financial statement amounts below are in U.S. dollars.
Business context
USANA develops and manufactures nutrition, food, personal care, and skincare products sold internationally through independent Associates and Preferred Customers. It reported approximately 617,000 active customers, up 7.7% year over year. Asia Pacific generated 81.6% of sales; China alone generated $134.3 million.
Key financial metrics
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Net sales | $308.0 million | $266.6 million | Up 15.5%; up 9.3% excluding currency effects |
| Gross profit | $250.3 million | $220.6 million | Up 13.5% |
| Gross margin | 81.3% | 82.7% | Down 1.4 percentage points |
| Operating earnings | $44.2 million | $39.0 million | Up 13.3% |
| Net earnings | $30.6 million | $26.6 million | Up 15.3% |
| Diluted EPS | $1.45 | $1.23 | Up 17.9% |
| Operating cash flow | $19.7 million | $30.8 million | Down $11.1 million |
| Cash and cash equivalents at period end | $257.0 million | $311.9 million at prior fiscal year-end | Down $54.9 million |
Associate incentives were $134.5 million, or 43.7% of sales, versus 43.5% a year earlier. Selling, general and administrative expense was $71.6 million; management said it declined as a share of sales due to higher revenue, despite rising in absolute dollars. The effective tax rate fell to 30.9% from 32.2%. The filing does not provide a clear net-debt balance; it reports no borrowings under the credit facility at April 3, 2021.
At April 3, 2021, current assets were $373.2 million and current liabilities were $151.5 million. The resulting current ratio was approximately 2.46, compared with approximately 2.53 at January 2, 2021. The $75 million revolving credit facility was undrawn; the agreement includes a minimum rolling four-quarter EBITDA covenant of $100 million and a maximum funded-debt-to-EBITDA ratio of 2.0 to 1.0.
Material changes and drivers
- Sales growth reflected customer growth and favorable currency movements, which added approximately $16.6 million to reported sales. Constant-currency sales increased 9.3%.
- Sales increased across all reported regions. Asia Pacific sales grew 16.6% reported and 9.3% excluding currency; Americas and Europe grew 11.1% reported and 9.3% excluding currency.
- Gross margin declined due to a market-specific promotion, sales mix, and higher relative shipping costs associated with COVID-19-related logistics disruption; favorable exchange rates partially offset these effects.
- Net earnings rose, supported by higher sales and lower relative operating expenses. Diluted EPS also benefited from a lower diluted share count.
- Operating cash flow declined year over year, with management citing payments for the prior-year employee bonus, inventory accruals, insurance, and certain IT contracts.
- USANA repurchased and retired 721,000 shares for approximately $69.5 million during the quarter. The remaining authorized repurchase amount was $80.5 million at quarter-end.
Outlook, commentary, and risks
The filing provides no numerical revenue or earnings guidance. Management said it expects to fund operations with cash generated from operations and considers liquidity sufficient for foreseeable needs. It plans to align spending with sales and defer non-essential capital investment while pandemic uncertainty persists.
Management said COVID-19 had not materially affected overall results for the quarter, but continued to disrupt in-person selling and events and had affected some sourcing, shipping, and logistics. It warned that impacts could continue through 2021 and remain difficult to predict. Production facilities were operating, and the company reported no meaningful supply-chain disruption as of the filing date.
Principal risks include dependence on direct selling and Associates; regulation of direct selling, particularly in China; uncertainty in China operations and remittance of profits; pandemic-related effects; foreign-exchange movements; supply-chain disruption; data privacy and security; and compliance with credit covenants. The company disclosed ordinary-course legal matters that management did not believe would materially adversely affect results, liquidity, or financial condition, though outcomes and potential changes could not be assured. An April 21, 2021 credit-agreement amendment updated LIBOR-related terms.
Important facts for investors to verify
- Confirm the reporting-period discrepancy: the supplied metadata says 2020 Q1, while the filing covers the quarter ended April 3, 2021.
- Assess whether customer growth and sales momentum—particularly in Southeast Asia Pacific and the Americas and Europe—are sustainable without prior incentive programs and favorable currency effects.
- Monitor gross margin, shipping costs, and operating cash conversion; operating cash flow was substantially below the prior-year quarter.
- Review the scale and pace of share repurchases against cash balances, liquidity needs, and the remaining authorization.
- Track COVID-19 effects, China-related regulatory and remittance risks, foreign-exchange exposure, and the company’s continued compliance with credit covenants.